Title:
HUMANIZED ANTI-VEGFR2 SINGLE-CHAIN ANTIBODY AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/042653
Kind Code:
A1
Abstract:
The present invention belongs to the field of antibody medicines and relates to a humanized anti-VEGFR2 single-chain antibody and a use thereof. The single-chain antibody comprises a heavy-chain variable region with a sequence as shown in SEQ ID No.1 and a light-chain variable region with a sequence as shown in SEQ ID No.2; furthermore, the heavy-chain variable region and the light-chain variable region are linked by a flexible peptide, wherein an amino acid sequence of the flexible peptide is SEQ ID No.3. Further disclosed is a use of the antibody in preparing products for inhibiting tumor growth. The antibody of the present invention can serve as a medicine for clinical use of indications caused by neovascularization.
Inventors:
GUO ZHIGANG (CN)
SHEN BINGHUI (CN)
WU LAOSHENG (CN)
SHEN BINGHUI (CN)
WU LAOSHENG (CN)
Application Number:
PCT/CN2019/084875
Publication Date:
March 05, 2020
Filing Date:
April 29, 2019
Export Citation:
Assignee:
ZHEJIANG BLUE SHIELD PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K39/395; C07K16/28; A61P15/14; A61P35/00
Foreign References:
| CN109111521A | 2019-01-01 | |||
| CN103965356A | 2014-08-06 |
Attorney, Agent or Firm:
NANJING SUGAO PATENT AND TRADEMARK FIRM(ORDINARY PARTNERSHIP) (CN)
Download PDF: